Navigation Links
BioMS Medical Announces Second Quarter 2008 Results
Date:8/12/2008

ated net loss of $24.6 million or ($0.31) per share for the same period of 2007.

Revenue for the three months ended June 30, 2008 was $11.2 million compared to $nil for the same period of 2007. Revenue for the six months ended June 30, 2008 was $24.0 million compared to $nil for the same period of 2007. The revenue is the result of recognizing a portion of the upfront payment received on the completion of the licensing agreement with Eli Lilly and Company.

Total consolidated expenses for the three months ended June 30, 2008 were $11.4 million compared to $12.1 million for the same period of 2007. Total consolidated expenses for the six months ended June 30, 2008 were $33.6 million compared to $25.4 million for the period of 2007.

Research and development expenses for the three months ended June 30, 2008 totaled $9.3 million compared to $10.2 million for the three months ended June 30, 2007. It is expected that total research and development expenses will remain constant over the next two years as the MAESTRO-01 and MINDSET-01 clinical trials near completion and MAESTRO-02 and MAESTRO-03 increase in number of patients under treatment. General and administrative expenses were $1.7 million for the three months ended June 30, 2008 compared to $1.5 million for the three months ended June 30, 2007.

At June 30, 2008, cash and short-term investments totaled $96.1 million as compared to $38.0 million at December 31, 2007. At June 30, 2008, the Corporation had working capital of $93.1 million (excluding the current portion of deferred revenue which does not represent a cash obligation) as compared to $34.8 million at December 31, 2007. Management estimates that the current working capital is sufficient for the Corporation to meet its obligations in respect of the currently initiated clinical trials for which it is responsible under the Lilly agreement.

As at June 30, 2008 there were 91,163,323 common shares of the Corporation issued and outs
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ... increased its investment in Green Chemistry and donated more ... last year, the Company announced Monday in its new ... the World? The report comes in ... being a responsible corporate citizen, including recognition for the ...
(Date:7/29/2014)... G-CON Manufacturing Inc., the standard in design and ... leadership appointment designed to drive the company’s ambitious growth ... Maik Jornitz, Chief Operating Officer of G-Con Manufacturing, has ... the pioneering company through its next phase of market ... and look forward to providing our next generation of ...
(Date:7/29/2014)... July 29, 2014 Dr. Jason Wendel – ... and named one of the Top 10 Plastic Surgeon Specialists ... skin care products. His complete line includes a Hydration Booster, ... give the face and skin a younger, more radiant appearance ... “Everyone’s skin is different, that is why at Dr. J. ...
(Date:7/28/2014)... A new method of building materials using light, developed ... day enable technologies that are often considered the realm ... devices. , Although cloaked starships won,t be a ... have developed for constructing materials with building blocks a ... to control the way that light flies through them, ...
Breaking Biology Technology:Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3G-CON Manufacturing, Inc. Announces Maik Jornitz as President 2Dr. J. J. Wendel Launches New Line of Skin Care Products 2Building 'invisible' materials with light 2
... The Netherlands, June 24 The U.S. Department,of Energy,s ... to enable the sale and delivery of an Avantium ... PNNL to,accelerate its catalyst research for infrastructure compatible biofuels ... by Battelle for the U.S. Department of Energy. The,Laboratory ...
... New Report Calls for a Broad Ethics of Emerging Technologies ... of synthetic biology will allow researchers to create biological parts ... to re-engineer existing organisms to perform novel and beneficial tasks. ... to addressing ethical and social issues is called for, especially ...
... WA, and VANCOUVER, June 24 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... the company has reached an agreement with the U.S. ... assessment process (SPA) on an amendment to the design ... lead product candidate targeting castrate resistant prostate cancer (CRPC). ...
Cached Biology Technology:Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA 2Does Synthetic Biology Need Synthesized Ethics? 2Does Synthetic Biology Need Synthesized Ethics? 3OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 2OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 3OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 4OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 5
(Date:7/29/2014)... researchers have developed an easier method to create ... work involved in diagnosing diseases. , DNA linked ... strong partnership that can be used in diagnostic ... which tag proteins with DNA can be ... and visualisation of biological material. The method also ...
(Date:7/29/2014)... There,s some good news for parents of preterm babies ... that by the time they become teenagers, the brains of ... born at term. , A study conducted by the University,s ... as the preterm child experiences no brain injury in early ... as good as their term-born peers. , However, the results ...
(Date:7/28/2014)... already approved by the U.S. Food and Drug Administration ... of certain bacterial pathogens inside human cells, including those ... The findings, published in mBio , the online ... a new way of identifying non-antibiotic drugs that could ... handful of drugs on the list inhibit the growth ...
Breaking Biology News(10 mins):New method provides researchers with efficient tool for tagging proteins 2Preterm children's brains can catch up years later 2New route to identify drugs that can fight bacterial infections 2
... predicted to occur under climate change scenarios has led many ... of wildfires. But a new study in the May issue ... changes in the types of plants growing in an area ... Philip Higuera of Montana State University and his colleagues ...
... Orleans, LA Sharell Bindom, a student in the ... will be awarded the Mead Johnson Research Award in ... the 2009 Experimental Biology Meeting April 18-22 in New ... is intended to recognize the graduate student, resident, or ...
... do all sorts of work, but a fundamental question has ... "There,s no little man sitting there, putting the protein ... biologist at the USC College of Letters, Arts and Sciences. ... tells them where to go in the cell." In ...
Cached Biology News:Plants could override climate change effects on wildfires 2Autopilot guides proteins in brain 2
... yolk protein Vtg in plasma from juvenile or ... for endocrine disrupting chemicals (EDCs) with estrogenic effects ... accepted screening test for the estrogenic effects of ... kit is a double-antibody immunometric (sandwich) EIA for ...
... acid synthetic peptide whose sequence corresponds to residues 115-133 of rat ... terminus): V115 - L - P - S - E ... V - P - N - E - V - L ... been added to facilitate conjugation and is not a part of ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
Biology Products: